Back to the future: using aminoglycosides again and how to dose them optimally. - sprookjes - yvandenbroek - TriplyDB

Back to the future: using aminoglycosides again and how to dose them optimally.

Back to the future: using aminoglycosides again and how to dose them optimally.

http://www.wikidata.org/entity/Q36916092

about

Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer Managing infective endocarditis in the elderly: new issues for an old disease.Therapeutic drug monitoring of amikacin in septic patients.Aminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt.Synthesis and spectrum of the neoglycoside ACHN-490 Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin.Optimization of aminoglycoside therapy.Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations.Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Optimizing the initial amikacin dosage in adults.Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design How aminoglycosides are used in critically ill patients in a teaching hospital in North of Iran Validation and Application of a Dried Blood Spot Ceftriaxone Assay.Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen.Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.Pharmacokinetics and pharmacodynamics of antibacterial agents.Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.Validation and Application of a Dried Blood Spot Assay for Biofilm-Active Antibiotics Commonly Used for Treatment of Prosthetic Implant Infections.Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units.Aminoglycoside drugs in clinical practice: an evidence-based approach.Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.Pharmacological rationale for antibiotic treatment of intra-abdominal infections.Mortality in a heterogeneous population of low-risk febrile neutropenic patients treated initially with cefazolin and tobramycin.Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.Selection of antibiotics for meticillin-resistant Staphylococcus pseudintermedius: time to revisit some old drugs?Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.Aminoglycoside-induced nephrotoxicity--a focus on monitoring: a review of literature.Strategies for the safe use of colistin.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.

P2860

Q26825326-54D80A46-7D15-4804-896B-24661655A345 Q30245399-4D462A9D-F27A-46CA-8EA4-01C4FFCB59DA Q33754166-2163B2D4-9448-4BBA-8E99-6661B795CB88 Q33831880-336B6BB1-F5E0-4804-BE45-178E7042724A Q34134992-E9CD1EA7-F9C8-4D29-89A2-029735F7929D Q34274190-0BB253BC-2A0D-4D56-8D87-73EC16EAFABE Q34290150-326D9850-C74E-42F1-87B8-050DB3600C84 Q34476089-425F88A9-C8CD-450D-8E33-FAE6106F6BAA Q34597640-DD249A5C-D5F6-4A66-82AC-1FBD43CEBEF1 Q34632230-B402A1A9-8910-4B66-9F78-481B32F8471C Q34694922-E6349F87-6CC2-4160-BDEB-A2C0B50A70A1 Q35005127-28E88560-B828-4865-8FE2-E9A5F4F4B478 Q35270270-36D8DEBC-2919-483D-AB7D-64974062C2E9 Q35755665-F8979FFB-546E-4E97-B540-A0900C844C73 Q35977417-528CF882-BBBC-49EB-8152-7843EB17FC87 Q36063806-0A6DD5E5-7E48-4D3C-B815-E40F9542F947 Q36082913-48F302C4-FA34-4C55-A07A-929F81004AF3 Q36083619-03CC848F-3F88-4DC9-9762-1DD2751F99C7 Q36158283-17B2556D-D97E-44BE-B73C-BC3DFFFBB62E Q36172460-C5095C6D-A151-4E56-8C7B-78001BD53061 Q36172505-E93D55C0-AE22-4991-AADD-38627A0398FA Q36290910-C210107A-DA79-478E-AF10-07EA79376544 Q36439065-53C36C5B-DAFA-4069-804B-BCDE35750A7C Q36505481-FC1F29AC-D95E-4280-A01A-21EF6AFE39A1 Q36644902-787717EC-521B-47C5-A2C9-44CEB11BDB39 Q36911111-0CC88AF0-F25C-40FE-98B0-97F1C688B266 Q37119964-D8189C36-858E-495D-B029-00FA8077C6AE Q37120112-25CDF71F-9F40-4367-AEC5-1938A41C198D Q37247721-DFAF5318-BFA6-403E-9096-710EFD483443 Q37331044-D7BDCED6-0705-4AD7-BC17-E636F85A6B1D Q37335803-F9A27E82-69E6-41EB-B063-381D88C47486 Q37358664-201E48FF-2E67-41FB-851A-2803726E7E8E Q37557851-9E77348E-EDEE-4523-BF8F-FCCB1E0DF812 Q37814101-0FB184AE-6C04-495A-AB4E-8A26E7D99A8F Q37867260-B0D0C88D-5DA4-4E25-B066-5363E7608C34 Q37982099-53E562F7-44BA-4529-B32B-9FDA941C2CB5 Q38090988-2DC1C51B-5F1F-4557-B067-AAAB27646F1A Q38239999-4FE3DCFD-FF70-4D9E-8CEF-E523C2E4E630 Q38548658-50918DC0-A471-4869-B5DC-4FB2AD41506F Q38672016-1CCD296F-403E-45B8-9935-5535DA9C6986

P2860

Back to the future: using aminoglycosides again and how to dose them optimally.

http://www.wikidata.org/entity/Q36916092

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Back to the future: using aminoglycosides again and how to dose them optimally.

@en

type

label

Back to the future: using aminoglycosides again and how to dose them optimally.

@en

prefLabel

Back to the future: using aminoglycosides again and how to dose them optimally.

@en

P1433

Q36916092-1E4D4C7A-B795-4BA4-A39F-EB680DF118C7

P1476

Q36916092-0F3D843E-AC07-43A3-A002-9881D026754C

P2093

Q36916092-3E264B7C-8756-47D8-A39D-91E88195E28B

Q36916092-571840E8-E49D-4A48-9815-DAF05E349654

Q36916092-5D1D1288-D7B6-4010-A251-7AAB1E07CE82

Q36916092-5F4620A4-5A8C-4AF8-A04B-CC600554C81C

Q36916092-CAA8577F-869C-45E7-820A-F3AB1787DBA4

Q36916092-F833DB29-8244-4C72-9325-82DC56833A43

P2860

Q36916092-2DFD150E-265D-4289-B22C-50AD1E2A3A68

Q36916092-37967BBD-29BF-4360-AAAF-616D88E25ACD

Q36916092-60E0BE59-EAB9-4AF1-941C-60800006FEE7

Q36916092-AFD1BDE5-AB75-43BC-AF94-BF79436DB8F6

Q36916092-B6A78C8A-4099-4D8F-8D46-60EE84362994

Q36916092-DAC87C3D-7A26-4FB7-A211-D3BFD3007316

Q36916092-E3A14B41-BAAB-4A67-81AB-8B83724293DD

Q36916092-F72AE723-1616-45BC-84B5-89FAA6DEAB04

P304

Q36916092-8A7CD0CF-348F-4DA2-AFEE-8DA5BFB98C14

P31

Q36916092-84EFB3BE-15D8-430F-864D-532CABA2C094

P356

Q36916092-0C79F659-8BF2-4FB1-BC57-A66428C3C83F

P407

Q36916092-A8A58B9F-8165-44DF-9E78-5EF5F513B705

P433

Q36916092-6B3083BF-E416-42FB-8A84-F30BDA6BB14C

P478

Q36916092-568EF65B-A8BC-4060-8788-6089DEF8FF0F

P577

Q36916092-33A95DD7-38A7-497D-BD8D-BD688F542B21

P5875

Q36916092-3FD04C67-2581-46AC-B401-7E2AC79A0D1D

P698

Q36916092-0AF5D20F-9F4A-4109-9890-DF11318A0A75

P356

P1433

Clinical Infectious Diseases

P1476

Back to the future: using aminoglycosides again and how to dose them optimally.

@en

P2093

Ann N Nafziger

http://www.w3.org/2001/XMLSchema#string

Arnold Louie

http://www.w3.org/2001/XMLSchema#string

George L Drusano

http://www.w3.org/2001/XMLSchema#string

Joseph S Bertino

http://www.w3.org/2001/XMLSchema#string

Paul G Ambrose

http://www.w3.org/2001/XMLSchema#string

Sujata M Bhavnani

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring.

Nonparametric approach to population pharmacokinetics in oncology patients receiving aminoglycoside therapy.

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia.

The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess.

Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.

P304

753-760

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/520991

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2007-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6126704

http://www.w3.org/2001/XMLSchema#string

P698

17712761

http://www.w3.org/2001/XMLSchema#string